To the Editor: Powles et al. (Sept. 24 issue)(1) report the practice-changing results of the JAVELIN Bladder 100 trial, which assessed the advantage of maintenance avelumab therapy plus best supportive care over best supportive care alone with respect to overall survival among patients with advanced urothelial carcinoma who had had a response to first-line chemotherapy. A total of 43.7% of the patients in the best supportive care (control) group received immunotherapy as subsequent therapy; this finding indicates that starting immunotherapy early rather than waiting for disease progression is beneficial. The combination of chemotherapy and immunotherapy as up-front treatment does not . . .
Mollica V., Rizzo A., Massari F. (2020). Avelumab maintenance for urothelial carcinoma. THE NEW ENGLAND JOURNAL OF MEDICINE, 383(25), 2482-2483 [10.1056/NEJMc2032018].
Avelumab maintenance for urothelial carcinoma
Mollica V.;Massari F.
2020
Abstract
To the Editor: Powles et al. (Sept. 24 issue)(1) report the practice-changing results of the JAVELIN Bladder 100 trial, which assessed the advantage of maintenance avelumab therapy plus best supportive care over best supportive care alone with respect to overall survival among patients with advanced urothelial carcinoma who had had a response to first-line chemotherapy. A total of 43.7% of the patients in the best supportive care (control) group received immunotherapy as subsequent therapy; this finding indicates that starting immunotherapy early rather than waiting for disease progression is beneficial. The combination of chemotherapy and immunotherapy as up-front treatment does not . . .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
